Exelixis (EXEL) Change in Acquisitions & Divestments (2010 - 2026)
Exelixis' (EXEL) quarterly Change in Acquisitions & Divestments came in at $225.1 million in Q2 2026, down 13.05% year-on-year from $258.9 million in Q2 2025, and up 18.9% quarter-over-quarter from $189.3 million in Q1 2026.
Exelixis (EXEL) Change in Acquisitions & Divestments (2010 - 2026) Analysis & Trends
Exelixis' Change in Acquisitions & Divestments history runs 17 years deep, the most recent figure standing at $225.1 million for Q2 2026.
- On a quarterly basis, Change in Acquisitions & Divestments fell 13.05% year-over-year to $225.1 million in Q2 2026; TTM through Apr 2026 was $989.1 million, a 13.98% increase from a year earlier, with the FY2026 full-year figure at $1.0 billion, up 16.59% from the prior year.
- Change in Acquisitions & Divestments rose to $225.1 million in Q2 2026 per EXEL's latest filing, from $189.3 million in the prior quarter.
- Across five years, Change in Acquisitions & Divestments topped out at $353.1 million in Q3 2025 and bottomed at $153.5 million in Q4 2023.
- The 5-year median for Change in Acquisitions & Divestments is $238.0 million (2022), against an average of $248.7 million.
- Across the five-year window, Change in Acquisitions & Divestments slumped 46.18% in 2024 and soared 64.02% in 2025, its largest moves.
- Year by year, Change in Acquisitions & Divestments stood at $238.0 million in 2022, then plunged by 35.5% to $153.5 million in 2023, then rose by 9.07% to $167.4 million in 2024, then surged by 32.31% to $221.5 million in 2025, then increased by 1.63% to $225.1 million in 2026.
- Per Business Quant, the three latest EXEL Change in Acquisitions & Divestments figures stand at $225.1 million (Q2 2026), $189.3 million (Q1 2026), and $221.5 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn |
| 10 | Exelixis | 14.48 Bn | 13.70 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 225.13 Mn |
| Apr 3, 2026 | 225.13 Mn |
| Jan 2, 2026 | 189.34 Mn |
| Jan 2, 2026 | 189.34 Mn |
| Oct 3, 2025 | 221.51 Mn |
| Oct 3, 2025 | 221.51 Mn |
| Jul 4, 2025 | 353.10 Mn |
| Jul 4, 2025 | 353.10 Mn |
| Apr 4, 2025 | 258.92 Mn |
| Apr 4, 2025 | 258.92 Mn |
| Jan 3, 2025 | 226.16 Mn |
| Jan 3, 2025 | 226.16 Mn |
| Sep 27, 2024 | 167.42 Mn |
| Sep 27, 2024 | 167.42 Mn |
| Jun 28, 2024 | 215.28 Mn |
| Jun 28, 2024 | 215.28 Mn |
| Mar 29, 2024 | 268.45 Mn |
| Mar 29, 2024 | 268.45 Mn |
| Dec 29, 2023 | 153.49 Mn |
| Dec 29, 2023 | 153.49 Mn |